HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Victor A Gault Selected Research

gastric inhibitory polypeptide receptor

1/2020Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes.
2/2009Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intolerance.
12/2007GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.
6/2007Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.
2/2007Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.
7/2006Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16).
9/2005A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.
8/2005Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes.
10/2003Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?
2/2002Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Victor A Gault Research Topics

Disease

35Insulin Resistance
01/2021 - 06/2003
32Type 2 Diabetes Mellitus (MODY)
01/2021 - 02/2002
31Body Weight (Weight, Body)
01/2021 - 09/2004
26Obesity
01/2021 - 11/2002
5Alzheimer Disease (Alzheimer's Disease)
02/2012 - 04/2007
4Inflammation (Inflammations)
01/2018 - 11/2014
3Cognitive Dysfunction
01/2018 - 04/2007
3Neurodegenerative Diseases (Neurodegenerative Disease)
01/2018 - 06/2008
2Glucose Intolerance
02/2009 - 02/2006
2Hypertrophy
12/2007 - 08/2005
1Weight Loss (Weight Reduction)
01/2021
1Short Bowel Syndrome
01/2021
1Metabolic Diseases (Metabolic Disease)
01/2021
1Body Weight Changes
01/2020
1Gliosis
01/2018
1Neuroinflammatory Diseases
01/2018
1Amyloid Plaque
02/2012
1Hyperplasia
08/2005
1Overnutrition
10/2003
1Diabetes Mellitus
11/2002

Drug/Important Bio-Agent (IBA)

43Glucose (Dextrose)FDA LinkGeneric
01/2021 - 02/2002
34Insulin (Novolin)FDA Link
01/2021 - 11/2002
26Peptides (Polypeptides)IBA
01/2020 - 11/2002
16Glucagon-Like Peptide 1 (GLP 1)IBA
01/2021 - 01/2004
13xenin 25 (xenin)IBA
01/2021 - 08/2012
11Hormones (Hormone)IBA
01/2018 - 10/2003
10gastric inhibitory polypeptide receptorIBA
01/2020 - 02/2002
8Glucagon (Glukagon)FDA Link
01/2021 - 12/2003
7Blood Glucose (Blood Sugar)IBA
01/2021 - 01/2016
7IncretinsIBA
01/2018 - 12/2003
6Triglycerides (Triacylglycerol)IBA
01/2018 - 12/2007
6EnzymesIBA
01/2018 - 02/2002
6Pro(3)- glucose-dependent insulinotropic polypeptideIBA
12/2007 - 02/2002
5Biological ProductsIBA
01/2021 - 08/2003
5Pharmaceutical PreparationsIBA
01/2018 - 12/2004
4LiraglutideFDA Link
01/2020 - 08/2010
4Hypoglycemic Agents (Hypoglycemics)IBA
01/2018 - 01/2004
3dapagliflozinIBA
01/2020 - 09/2017
3Exenatide (Byetta)FDA Link
09/2018 - 01/2018
3OxyntomodulinIBA
11/2014 - 12/2010
3PalmitatesIBA
08/2012 - 11/2002
3monomethoxypolyethylene glycol (MPEG)IBA
12/2010 - 06/2008
2Sitagliptin Phosphate (Januvia)FDA Link
01/2021 - 01/2020
2Streptozocin (Streptozotocin)FDA Link
01/2020 - 01/2020
2LipidsIBA
01/2020 - 01/2018
2AmylasesFDA Link
09/2018 - 01/2018
2Neuroprotective AgentsIBA
01/2018 - 11/2014
2Proteins (Proteins, Gene)FDA Link
11/2014 - 02/2012
2AdiponectinIBA
02/2009 - 06/2008
2Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
07/2007 - 04/2006
2Amyloid beta-PeptidesIBA
06/2007 - 04/2007
2Gastrointestinal Hormones (Hormones, Gastrointestinal)IBA
09/2006 - 09/2005
2Fatty Acids (Saturated Fatty Acids)IBA
02/2006 - 09/2005
1O-(Chloroacetylcarbamoyl)fumagillol (TNP 470)IBA
01/2021
1methionine aminopeptidase 2IBA
01/2021
1Pyruvic Acid (Pyruvate)IBA
01/2021
1AntibodiesIBA
01/2020
1Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)IBA
01/2020
1Ala(2)- glucose-dependent insulinotropic polypeptideIBA
01/2020
1GastrinsIBA
09/2018
1epigallocatechin gallate (epigallocatechin-3-gallate)IBA
01/2018
1Glucagon-Like Peptide-1 Receptor AgonistsIBA
01/2018
1Therapeutic UsesIBA
01/2018
1CholesterolIBA
01/2018
1Glutamine (L-Glutamine)FDA Link
04/2016
1lixisenatideIBA
11/2014
18-hydroxyguanineIBA
11/2014
1Carbon MonoxideIBA
05/2014
1Peptide FragmentsIBA
05/2014
1AcidsIBA
06/2013
1gastric inhibitory polypeptide (3-42)IBA
05/2012
1Amyloid (Amyloid Fibrils)IBA
02/2012
1Congo RedIBA
02/2012
1Presenilin-1IBA
02/2012
1ResistinIBA
02/2009
1amyloid beta-protein (25-35)IBA
06/2008
111-beta-Hydroxysteroid Dehydrogenases (11beta Hydroxysteroid Dehydrogenase)IBA
04/2008
1CarbenoxoloneIBA
04/2008
111-beta-Hydroxysteroid Dehydrogenase Type 1IBA
04/2008
1Dipeptidyl-Peptidase IV InhibitorsIBA
07/2007
1Hyp(3)-palmitoylLys(16)- glucose-dependent insulinotropic polypeptideIBA
06/2007
1Hyp(3)- glucose-dependent insulinotropic polypeptideIBA
06/2007
1Free RadicalsIBA
04/2007
1exendin (9-39)IBA
02/2007
1Metformin (Glucophage)FDA LinkGeneric
10/2006
1BiguanidesIBA
10/2006
1Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA
10/2006
1Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA
09/2006
1Pituitary Adenylate Cyclase-Activating Polypeptide ReceptorsIBA
09/2006
1N-AcGIP(LysPAL37)IBA
04/2006
1Insulin SecretagoguesIBA
01/2004
1Cyclic AMP (AMP, Cyclic)IBA
01/2004

Therapy/Procedure

12Therapeutics
01/2021 - 10/2003
3Intraperitoneal Injections
12/2007 - 02/2006
3Injections
06/2007 - 09/2005
1Withholding Treatment
08/2005